* failure to discuss trial design with regulatory authority
* do discuss trial design with regulatory authority, but fail to follow their advice
* do discuss trial design with regulatory authority, and do follow their advice. Later, when the regulatory authority is assessing the new drug application, the old staff has left and the new staff have different ideas.
Pillar 2 - Breast Cancer, page-91
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.78 |
Change
-0.005(0.28%) |
Mkt cap ! $303.3M | |||
| Open | High | Low | Value | Volume |
| $1.80 | $1.84 | $1.78 | $133.8K | 73.76K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 15072 | $1.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.87 | 1793 | 1 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |